Back to top

Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data

Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Neurogene Inc. (NGNE)

Taysha Gene Therapies, Inc. (TSHA)